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Summary
Introduction:  On  the  basis  of  a  case  of  hypodermal  metastasis  of  malignant  melanoma  to  the
cheek and  a  review  of  the  literature,  we  analyze  treatment  and  recent  progress  in  metastatic
malignant  melanoma.
Case-report:  A  55-year-old  woman  presented  with  a  facial  hypodermal  metastasis  of  a  slow-
growing melanoma  of  the  ankle  that  had  been  treated  by  surgery.
Discussion/conclusion:  Metastatic  malignant  melanoma  treatment,  which  was  usually  palliative
when surgical  resection  was  not  feasible,  has  been  improved  by  innovations  in  immunotherapy
(ipilimumab)  and  targeted  therapy  (vemurafenib).  Genetic  proﬁling  is  an  interesting  line  of
research to  improve  short-term  prognosis  in  these  tumors.
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Introduction
Melanoma  is  an  aggressive  tumor  with  an  incidence  that
is  constantly  increasing  in  developed  countries  [1]. Prog-
nosis  is  excellent  in  early  stages,  when  simple  surgical
resection  and  revision  of  the  margins  is  often  sufﬁcient,
but  the  disease  becomes  swiftly  life-threatening  when  it
begins  to  spread.  Based  on  a  case  of  jugal  melanoma
of  particularly  slow  evolution  and  a  review  of  the  litera-
ture,  the  present  study  discusses  management  of  cutaneous
melanoma  and  recent  progress  in  the  treatment  of  advanced
forms.
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ase report
 55-year-old  woman  presented  with  a bluish  hypoder-
al  nodule  of  3  months’  evolution  in  the  right  mandibular
roove.  In  1985,  she  had  been  operated  on  for  a  dysplas-
ic  nevus  on  the  left  ankle  and,  in  1991,  for  a  lesion  at
he  scar  which  histology  found  to  be  melanoma.  In  1999,
wo  hypodermal  nodules  appeared  on  the  left  calf  and  she
as  placed  under  surveillance.  One  nodule  regressed  spon-
aneously,  and  the  remaining  nodule  was  resected  in  2009.
athologic  analysis  indicated  hypodermal  metastasis  of  the
elanoma.  Treatment  by  recombinant  interferon  alfa-2a
Roferon®) was  initiated  but  terminated  6  months  later  for
iver  intolerance.  The  patient  informed  us  that  her  mother,
ged  90,  had  a  weakly  evolutive  multi-metastatic  melanoma
or  which  she  refused  treatment,  with  conserved  general
ealth  status.
served.
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iigure  1  Radiologic  aspect  of  hypodermal  lesion  on  contrast-e
The  nodule  was  hard,  painless  and  mobile,  measuring
 cm.  There  were  no  other  skin  or  lymph-node  lesions.  Fine-
eedle  aspiration  cytology  suggested  achromic  melanoma
etastasis.  PET  found  two  hyperﬁxed  lesions  facing  the  right
acial  pedicle  (Fig.  1).  Surgical  resection  was  performed,
ncluding  the  ipsilateral  lymph-node  levels  I to  V.  Pathologic
nalysis  diagnosed  hypodermal  metastasis  (Figs.  2  and  3)  of
elanoma.  There  was  no  lymph-node  extension.  Exploration
or  BRAF  and  c-kit  mutations  was  negative.  The  CDK4  and
DKN2A  genes  were  not  mutated  in  this  patient  or  in  her
other.  Eleven  months  after  surgery,  the  patient  showed  no
linical  or  paraclinical  (cervical  ultrasound  and  PET  scan)
igns  of  evolution.
iscussion
elanoma  is  a  malignant  tumor  the  incidence  of  which  is
teadily  increasing  in  the  developed  world  and  is  estimated
t  1/10  000  in  France  [1].  It  is  highly  lymphophilic,  with  high
etastatic  potential  [2].  The  main  metastasis  locations  are
he  skin  (in-transit  or  remote),  lungs,  liver  and  brain.
There  are  three  patterns  of  evolution:  slowly  evolv-
ng  superﬁcial  melanoma,  thick  melanoma  that  is  fast
igure  2  Large  cells  with  a  few  smaller  lymphocytes,
ndicative  of  metastasis;  an  aspect  of  mitosis  also  suggests  pro-
iferating  tumor  (×  100).
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tced  CT  (left),  T1-weighted  fatsat  MRI  (middle)  and  PET  (right).
rowing  without  sun  exposure  or  multiple  nevi,  and  cephalic
elanoma  with  sun  exposure  [2]. The  slow-growing  type
such  as  the  present  case)  may  account  for  the  stable  overall
ortality  associated  with  melanoma  despite  the  increasing
ncidence  of  superﬁcial  forms  and  the  stable  incidence  of
hick  forms  [3].
Ten  percent  of  cases  involve  hereditary  predisposition
4].  Genetic  assessment,  performed  on  clinical  suspicion,
nds  mutation  in  40%  of  cases  [4]. The  genes  principally
nvolved  are  MKR1, CDK4  and  CDKN2A.  Certain  genetic  pro-
les  are  indicative  of  prognosis  and  treatment  response.  For
xample,  analysis  of  type-1  interferon  can  correlate  certain
lleles  to  evolutivity  (metastasis  risk  and  overall  survival)
nd  treatment  efﬁcacy  [5]. Despite  similarities  in  evolution
etween  mother  and  daughter  in  the  present  case,  genetic
nalysis  found  no  anomaly.
At  the  metastatic  stage,  melanoma  in  incurable,  with
0—20%  2-year  survival  [6]. Palliative  radiation  therapy  is
ossible,  for  analgesic  or  functional  purposes.  Surgery  is
ndicated  in  case  of  single  location  where  no  major  func-
ional  impact  is  to  be  expected.  Thus,  monochemotherapy
as  used  in  most  cases  until  very  recently,  with  dacar-
azine  (Deticène®) as  the  reference  molecule.  Beneﬁt,
igure  3  Intranuclear  inclusion,  in  this  context  indicating  a
iagnosis  of  melanoma.  The  absence  of  pigment  is  noticeable,
nd classically  reported  in  metastasis  of  melanoma  as  opposed
o the  primary  tumor  (×  400).
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however,  was  debatable,  with  a  10%  response  rate  and  no
proven  impact  on  survival  [3,6].  This  relative  inefﬁcacy
of  systemic  treatment  now  needs  rethinking  in  the  light
of  several  trials  in  immunotherapy  and  targeted  therapy
[6—9].
Ideally,  the  immune  system  should  be  able  to  recognize
and  destroy  cancer  cells.  Tumors,  as  they  develop,  how-
ever,  induce  tolerance  in  the  host  organism  and  growth
outstrips  the  capacity  of  immune  reaction.  Immunotherapy
seeks  to  exploit  the  cytotoxicity  of  the  immune  system,
and  has  led  to  the  development  of  ipilimumab  (Yervoy®),
a  monoclonal  IgG1  antibody  that  blocks  the  CTLA-4  surface
protein  on  T  lymphocytes.  It  thereby  increases  the  activation
and  proliferation  of  these  cytotoxic  cells,  with  anti-tumoral
effect.  In  a  phase-III  study,  an  association  of  ipilimumab  to
dacarbazine,  compared  to  dacarbazine  alone,  signiﬁcantly
(P  <  0.001)  increased  overall  1-year  (47.3%  vs.  36.3%),  2-
year  (28.5%  vs.  17.9%)  and  3-year  survival  (20.8%  vs.  12.2%)
[6].  The  most  frequent  side  effects  are  dysimmunitary  (hep-
atitis,  enterocolitis,  thyroiditis,  hypophysitis,  uveitis,  etc.)
[6].
Progress  has  also  been  made  in  targeted  therapy.
Forty  to  60%  of  cutaneous  melanomas  show  activat-
ing  mutation  of  a  gene  coding  for  a  serine/threonine
kinase,  BRAF  protein  [7],  which  activates  the  MAP-kinase
pathway,  increasing  cell  proliferation  [7,8]. Vemurafenib
(Zelboraf®)  inhibits  the  kinase  function  of  mutated  BRAF
protein.  Compared  to  dacarbazine,  vemurafenib  signiﬁcan-
tly  reduces  disease-related  mortality  and  tumor  progression
(P  <  0.001),  increasing  overall  6-month  survival  (84%  vs.  64%)
[7,9].  Resistance,  however,  emerges  after  a  few  months’
treatment  [10].  Side  effects  are  primarily  dermatological
(photosensitivity,  keratoacanthoma,  squamous-cell  carci-
noma).
The  absence  of  BRAF  mutation  in  the  present  case  ruled
out  this  approach.  Moreover,  the  tumor’s  slow  spontaneous
evolution  and  accessibility  to  surgery  indicated  a  purely  sur-
gical  attitude  combined  with  regular  surveillance.  Ipsilateral
level  I-V  lymph-node  dissection  was  performed  as  the  PET
scan  suggested  lymph-node  involvement;  this  was  not  in  fact
found  on  deﬁnitive  histologic  analysis,  evidence  for  overes-
timation  of  lymph-node  pathology  on  PET,  which  argues  for
cautious  interpretation.
[191
onclusion
anagement  of  metastatic  melanoma,  which  used  to  be
urely  palliative  when  surgical  resection  was  not  feasible,
as  now  been  improved  by  the  advent  of  immunotherapeutic
olecules  such  as  ipilimumab  (anti-CTLA4  antibody)  and  tar-
eted  therapy  using,  for  example,  vemurafenib  (BRAF  kinase
nhibitor).  Screening  for  particular  genetic  proﬁles  would
lso  seem  to  be  an  interesting  line  of  research  to  improve
hort-term  prognosis  in  this  indication.
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